Neuropathy Resource Library

Low-level laser devices in the class 3B power range have been tested against sham treatment in peripheral neuropathy, and the results are mixed rather than absent. A 50-patient trial in Toronto found a trend toward pain relief that did not reach statistical significance; a 60-patient trial in Iran and a 200-patient trial in India each reported significant improvement in pain and neuropathy scores.^1,2,3 No single trial has been large enough, long enough, or similar enough to the others to settle the question.

The second thing worth knowing is who was in those trials. Every one of them enrolled a narrower group of people than the patients who actually walk into a neuropathy clinic. That is the part most articles skip, and it is the part that decides whether a published number applies to you.

This page walks through each trial: the device, the population, the exclusion criteria as the papers and trial registries state them, and what the design could not measure.

What “class 3B” actually means

The class is a safety label, not a dose

Laser class is a hazard classification. Under the federal performance standard at 21 CFR 1040.10, a Class IIIb laser product is one that permits human access during operation to laser radiation above the accessible emission limits of table III-A but not above those of table III-B; a Class IV product exceeds table III-B.⁴ The class describes how dangerous the beam is to an eye or to skin. It says nothing about whether the light helps a nerve.

Two devices in the same class can differ in wavelength, in whether the beam is continuous or pulsed, in how large an area is treated, and in how much energy actually reaches tissue. Two devices in different classes can deliver similar energy to similar depth if treatment time and area differ. Class 3B and class 4 are not two schools of therapy. They are two rungs on a safety ladder.

The numbers that matter are often missing from the papers

This is where pooling the literature breaks down. A 2016 analysis in Lasers in Medical Science reviewed 74 low-level light therapy and photobiomodulation articles indexed between March 2014 and March 2015 and found missing information for wavelength in 3% of papers, power in 41%, beam area in 40%, irradiance in 43%, pulse frequency in 52%, and radiant energy in 74%.⁵ The majority, 73%, gave no information about how light was measured and relied on manufacturer-stated values. Only 5% reported a complete dataset for the parameters assessed.

That is not a theoretical complaint. The Toronto trial reports a wavelength of 905 nm and an average power of 0 to 60 mW, but never states a dose in joules per square centimeter.¹ The Iranian trial reports an energy density of 2.5 J/cm² and, as printed, a wavelength of 78 nm — a figure in the extreme ultraviolet range that no therapeutic laser produces, and which the published paper repeats without correction.² Neither paper states a laser class at all.

So when someone asks what the trials show for “class 3B,” the honest first answer is that the trials mostly did not report themselves in those terms. What they reported was wavelength and, sometimes, power and dose. Reading them requires working from those numbers rather than from a class label.

The sham-controlled trials that used low-level devices

Toronto, 2004: 50 patients, 905 nm, up to 60 mW

This trial was run at the Diabetic Neuropathy Research Clinic of the Toronto University Health Network between October 2000 and February 2001.¹ Fifty patients with painful diabetic sensorimotor polyneuropathy, 34 men and 16 women, 88% of them with type 2 diabetes, received sham therapy for a two-week run-in and were then randomized to low-intensity laser or continued sham, twice weekly for four weeks — eight active sessions in total. The device was a Theralase TLC 5000 at 905 nm with an average power of 0 to 60 mW, applied for five minutes to two painful sites on each foot through a five-prong head covering a 6 cm diameter of skin.

Who was screened out. Eligible patients were adults aged 18 or older with polyneuropathy for at least three months, pain in both feet, and a pain score of at least 4 on the visual analog scale of the Short-Form McGill Pain Questionnaire. Analgesic and adjuvant analgesic medications were allowed if the regimen was unchanged. Excluded were patients with unstable medical conditions, the paper naming malignancy and active or untreated thyroid disease as examples, and patients with other neurologic diseases that would confound assessment of neuropathy. Pregnancy, metallic implants, alcohol or illicit drug use, and other severe pain symptoms that might confound self-evaluation of neuropathic pain were also exclusions.

What it found. Both groups improved during the sham run-in, a placebo response the authors put at roughly 20% pain reduction. After the four-week intervention, the laser group had an additional reduction in weekly mean pain of 1.0 ± 0.4 points compared with 0.0 ± 0.4 in the sham group, which did not reach statistical significance (P = 0.07). There was no effect on the Toronto Clinical Neuropathy Score, nerve conduction studies, sympathetic skin response, or quantitative sensory testing. The authors concluded that an encouraging trend was observed but the results did not provide sufficient evidence to recommend the treatment.

What the design could not capture. The authors said this themselves. They noted the study ran over a short period with a relatively small number of patients, that the potential benefit of low-intensity laser may be restricted to small nerve fibers that are difficult to assess accurately, and that more definitive results might have come from a larger sample and more frequent or longer treatment. They also recorded that no significant adverse effects occurred and that there was no concern about interactions in patients on multiple medications, so the treatment could be offered safely to patients with a wide spectrum of comorbid disease.

Kermanshah, 2013: 60 patients, twice weekly for a month

Sixty patients receiving care for diabetic sensorimotor polyneuropathy at a diabetes research center in Kermanshah, Iran, were matched on sex, age, body mass index, type and duration of diabetes, and duration of pain, then randomized by coin toss to laser or sham.² Participants were 77.7% female with a mean age of 56.1 years; diabetes duration ranged from 24 to 360 months and neuropathy duration from 4 to 96 months. Treatment was twice weekly for five minutes over one month, roughly eight sessions.

Who was screened out. Eligible patients were older than 18, diagnosed with polyneuropathy for more than three months, with pain in both feet and a visual analog score of at least 4. Patients on medication were eligible provided the regimen had not changed in the four weeks before the study. Excluded were patients with malignant disease, patients with thyroid disease who were not taking medication for it, and patients with neurological disorders that could interfere with evaluation. Pregnant women, patients with metal objects in the body, and patients using alcohol or psychotropic drugs were also removed.

What it found. In the laser group, visual analog and Toronto Clinical Neuropathy scores improved significantly from baseline at both two and four weeks (P < 0.0001), and the between-group difference against sham was significant (P < 0.0001). The sham group showed no significant change on either measure. Within the laser group, neuropathy scores at four weeks were not significantly better than at two weeks, so most of the change appeared early and then plateaued.

What the design could not capture. Follow-up ended four weeks after a one-month course, so nothing in this trial speaks to durability. The report gives an energy density but no power output, no treatment area, and no laser class, which makes the protocol difficult to reproduce or to pool with other studies.

Manipal, 2025: 200 patients, helium-neon at 632.8 nm

This is the largest of the low-level laser trials in this condition. Two hundred people with type 2 diabetes and peripheral neuropathy were randomized, 100 per arm, at a center in Manipal, India.³ The intervention arm received photobiomodulation for ten days using a low-level helium-neon laser at 632.8 nm and 3.1 J/cm² for nine minutes across the dorsal and plantar surfaces of the foot; the control arm received sham laser. Patients were assessed on day 0 and four weeks after treatment. The registered protocol also lists a second low-level device, a Thor laser at 660 and 850 nm with a power density of 50 to 150 mW/cm² applied over the popliteal fossa and the neck of the fibula; the published report describes the helium-neon component.⁶

Who was screened out. The trial registration lists inclusion as people aged 30 to 70 with type 2 diabetes and peripheral neuropathic pain who were willing to consent.⁶ Exclusions were patients with any other neurological disorder or morbid conditions; patients with another metabolic neuropathy, thyroid disorders given as the example; pregnant women; patients undergoing chemotherapy or radiation; and patients with diabetic peripheral neuropathy who had a foot ulcer.

What it found. The intervention group showed significant change four weeks after treatment in serum neuron specific enolase and calcitonin gene-related peptide, in Michigan Neuropathy Screening Instrument score, vibration perception threshold, numeric pain rating, and Norfolk quality-of-life score, all at P < 0.001. Nerve growth factor did not change (P = 0.937). The authors concluded that serum neuron specific enolase and calcitonin gene-related peptide may be good indicators of the effectiveness of photobiomodulation in reducing neuropathic pain and other symptoms.

What the design could not capture. Blinding was of participants only, not of assessors, which is weaker than the double-masked design used in Toronto. The exclusion list removes the two groups a neuropathy clinic sees constantly: people whose nerve injury has more than one driver, and people whose feet have already broken down. And ten days of treatment with a four-week assessment cannot say anything about a year from now.

What happens when these studies are pooled

A 2019 systematic review searched PubMed, Web of Science, CINAHL and Cochrane, screened 627 records and included six studies, randomized and non-randomized, using pain score, nerve conduction velocity and quality-of-life measures as outcomes.⁷ Its conclusion was that the evidence obtained shows low level laser therapy has a positive effect in controlling diabetic neuropathic pain. Six studies of mixed design is a small and uneven base, and the review says so by reporting its own numbers.

A 2025 review in Lasers in Medical Science looked at 23 clinical and preclinical studies published between 2015 and 2025 and focused specifically on dose.⁸ It reported the most consistent therapeutic effects at wavelengths of 630 to 670 nm and 808 to 904 nm, fluences of 3 to 10 J/cm², output power between 45 and 100 mW, and protocols of at least 12 sessions. It described photobiomodulation as a promising, safe and effective adjunctive therapy for diabetic neuropathy, and concluded that the absence of standardized dosimetry across studies remains a major challenge.

Two details in that parameter set are worth pausing on. An output power of 45 to 100 mW sits inside the class 3B range, not the class 4 range. And the session count matters: the Toronto and Kermanshah trials each delivered about eight sessions, and the Manipal trial ten — fewer than the twelve-session floor later associated with more consistent effect.

The class 4 trials, and why they are a separate question

Older adults with type 2 diabetes

The trial most often quoted in cold laser marketing used a class IV device, not a class 3B one. It was a pilot randomized, double-masked, sham-controlled study of 40 adults aged 60 and above with type 2 diabetes and painful diabetic peripheral neuropathy confirmed by nerve conduction velocity, recruited from the Department of Geriatric Medicine at AIIMS in New Delhi between April 2016 and September 2017.⁹ Participants were randomized 1:1 to deep tissue laser therapy or sham, twice weekly for four weeks and then weekly for eight weeks, sixteen sessions in total. Both arms continued standard-of-care treatment, so the trial tested laser as an addition to usual care rather than as a replacement for it.

The device was a Class IV medical laser delivering a blend of 980 nm and 810 nm light in an 80:20 optical power ratio, at 2 W continuous wave with an initial combined irradiance of 0.8 W/cm², over a plantar surface of roughly 120 to 200 cm². Class 3B units operate at substantially lower output, so this trial does not tell you what a class 3B device would do.

Who was screened out. The paper excluded patients with type 1 diabetes, lower-extremity open wounds, and psychotic, mood or neurological disorders that could interfere with the assessments. It also excluded patients with a life expectancy of less than three years and any malignancy treated with chemotherapy or radiotherapy in the previous two years. Patients were recruited irrespective of how long they had had neuropathy, so both newly diagnosed and long-standing cases were included.

What it found. Pain fell in both arms and significantly more in the active arm; on the Pain Disability Questionnaire the active group fell 60% (P < 0.001) against 28% in sham (P < 0.01). Quality of life improved significantly in the active group (P < 0.001) but not in sham (P = 0.194). Timed Up and Go times improved in both groups, and the improvement was 16% greater in the active group, but the authors reported that the ANOVA interaction for that difference was not statistically significant (P > 0.05). That correction matters: the function result was not a positive finding, and it should not be quoted as one.

What the design could not capture. The authors listed their own limits: no data on the duration of neuropathy, variable disease duration among participants, lack of statistical power for some comparisons, and a pilot design requiring validation in a multicenter trial with a larger cohort and longer follow-up.

Chemotherapy-induced neuropathy

Two class IV trials tested a different driver. In a randomized, double-blind, sham-controlled cross-over trial at the University of Minnesota, 70 patients with chemotherapy-induced peripheral neuropathy received 30-minute sessions three times weekly for six weeks using a class IV laser at 800 to 970 nm, 6.75 to 12 W per treatment zone, or a sham ceramic heat probe.¹⁰ Eligibility here was unusually broad: any adult with self-reported peripheral neuropathy and a history of chemotherapy exposure could enroll, including patients already diagnosed with neuropathy before chemotherapy and patients already on drug treatment for it, provided they did not change therapy during the study. The single stated exclusion was active cytotoxic cancer treatment within 30 days of enrollment.

Treated patients had a mean fall in modified total neuropathy score of 6.8 points, 52.6%, at eight weeks (P < 0.001), while sham patients changed by +0.2 points, 1.5% (P = 0.44). Adding physiotherapy to the laser did not improve the result over laser alone (difference 0.1 points, P = 0.85). The population, however, was entirely female and 98% non-Hispanic white, because it accrued through a gynecologic oncology clinic. Broad on comorbidity, narrow on demography.

The NEUROLASER pilot in Belgium took the opposite approach and tested prevention rather than treatment.¹¹ Thirty-two breast cancer patients receiving taxane chemotherapy were analyzed after 54 were randomized, using a class IV device at 905 and 808 nm, 0.168 W/cm² and 4 J/cm², twice weekly. Exclusions were extensive: prior neuropathy from another medical condition, being on a stable dose of medication for peripheral neuropathy such as duloxetine or pregabalin, metastatic disease, interruption of chemotherapy for more than two cycles, missing more than two consecutive laser sessions, and any reduction in chemotherapy dose. Neuropathy scores rose significantly over time in both arms (P < 0.001) and the difference between arms was not significant, though quality of life, the six-minute walk at follow-up (P = 0.035) and pain at follow-up (P = 0.058) favored the treated group. The authors named the small sample as their main limitation.

Who these studies left out

Line the exclusion lists up and a pattern appears. Across these six trials, the following people were kept out of at least one and usually several of them: patients with type 1 diabetes; patients with an open foot wound or ulcer; patients with any other neurologic disease; patients with a second metabolic driver such as thyroid disease; patients with cancer, or on chemotherapy or radiation, or with a life expectancy under three years; patients with other severe pain that would confound a pain questionnaire; patients whose medication regimen had changed recently; and, in the largest trial, patients over 70 or under 30, and anyone with unspecified “other morbid conditions.”

These are reasonable scientific choices. Removing competing explanations is how a trial isolates one variable. But the effect is that the published numbers describe a cleaner patient than the one sitting in the exam room. A person with type 2 diabetes, insulin resistance, a thyroid disorder, a healed ulcer, a recent change in gabapentin and eight years of symptoms would have been ineligible for most of this literature.

The conclusion cuts in both directions, and it should. A trend that missed statistical significance in 50 carefully selected patients does not establish that low-level laser fails in patients who were screened out. And a significant result in 200 carefully selected patients does not establish that it will help someone the trial would have excluded. What the exclusions establish is that the question has not been asked in the complex patient at all.

What none of these designs could measure

Four gaps run across the whole set.

Duration. Active treatment ran four weeks in Toronto, one month in Kermanshah, ten days in Manipal, twelve weeks in New Delhi and six weeks in Minnesota. The longest follow-up in any of them was 16 weeks. Nothing here measures durability at a year.

Combination and sequence. Only the New Delhi trial explicitly delivered laser on top of continuing standard care, and only the Minnesota trial tested adding a second modality, physiotherapy, which did not improve the result over laser alone. None of them tested light inside a sequenced program that first identifies and corrects the metabolic, nutritional, autoimmune or toxic driver. A single-modality trial cannot answer a combination question.

Outcome measures. Conventional nerve conduction studies mainly assess large myelinated fibers. The Toronto authors expected no electrophysiologic change and got none, and specifically raised the possibility that any benefit is in small fibers that these tests do not measure well. A trial can therefore report a null objective result while missing the fibers that carry burning and temperature sensation.

Dose. Because parameters were reported inconsistently, and in two of these papers incompletely or implausibly, the trials cannot be added together into a single answer about a single treatment. They are several different treatments sharing a label.

Where insurance sits, and why it is a separate question

Medicare maintains national coverage determination 270.6, Infrared Therapy Devices, effective for services on and after October 24, 2006.¹² It states that the use of infrared or near-infrared light or heat, including monochromatic infrared energy, is non-covered for the treatment of diabetic or non-diabetic peripheral sensory neuropathy and of wounds or ulcers of the skin or subcutaneous tissues, including pain arising from those conditions. The determination it followed was proposed in the CAG-00291N decision memorandum dated July 26, 2006.¹³

Two things are worth reading carefully. First, the NCD’s own description of the device category is an array of juxtaposed infrared diodes affixed to a flexible pad held in skin contact — a diode pad, not a laser. Second, a coverage determination is a payment decision made under the reasonable-and-necessary standard of the Social Security Act. It is not a clinical finding, and it does not report a trial result. Patients sign an Advance Beneficiary Notice for services a payer does not cover. Whether something is covered and whether something helps are two different questions, and a page that treats them as one is misleading its reader.

Why the driver matters more than the device

A laser cannot correct a nutritional deficit, an autoimmune process or a toxic exposure. Before adding a light-based therapy to a plan, the more useful question is which mechanism is currently damaging the nerve.

That is why our evaluation starts with identifying the driver — metabolic, nutritional, autoimmune, toxic or structural — rather than treating “neuropathy” as one condition. You can read how we sort those apart in the hidden drivers of peripheral neuropathy.

A 2025 review of laser therapy for neuropathic pain searched four databases for English-language studies published between January 2000 and June 2025, covering both low-level and high-intensity laser therapy across conditions including postherpetic neuralgia and diabetic neuropathy.¹⁴ The breadth of that literature is exactly why a single device label such as “3B” does not predict a result.

How we use class 3B cold laser at Regenerve

Regenerve offers class 3B cold laser alongside class 4 photobiomodulation and whole-body infrared. We use them as components of a physician-directed plan, after on-site electrodiagnostic testing and metabolic evaluation have identified what is driving the nerve injury, and alongside the metabolic and nutritional work that addresses that driver. We do not use light as a stand-alone treatment for nerve damage.

We do not promise nerve regeneration, reversal or cure, and we do not publish a success rate for our protocol. Our full list of testing and therapy options is on the Regenerve services page.

What we tell patients before starting

The conversation covers four things. What the published trials in your driver actually showed, including where they were negative. Whether you would have been eligible for those trials, and if not, what that does and does not imply. The safety record, which across these studies was benign — the Toronto trial reported no significant adverse effects and no concern about interactions in patients on multiple medications, and the Minnesota trial reported no complications among treated patients. And a defined point at which we stop and reassess rather than continuing indefinitely.

“My ethos is to treat all of my patients as I would my own family, with the goal of giving them back their quality of life.” — Dr. Gurpreet Singh Padda, MD, MBA, MHP

We see patients from the St. Louis region, Missouri and Illinois, at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. Call or text (314) 886-5902.

Start with your Nerve Damage Score

If you are weighing cold laser or any other therapy, start by finding out which driver is doing the most damage. The Nerve Damage Score is a free five-question screen that helps focus the first visit.

Frequently asked questions

Does class 3B cold laser therapy work for neuropathy?

The sham-controlled evidence for low-level devices in this power range is mixed. A 50-patient trial in Toronto found a trend that missed statistical significance at P = 0.07, while a 60-patient trial in Iran and a 200-patient trial in India each reported significant improvement in pain and neuropathy scores. All three enrolled selected populations, so the results describe those populations rather than every patient. See peripheral neuropathy treatments for the feet.

Is cold laser the same thing as infrared therapy for neuropathy?

No. Medicare’s national coverage determination 270.6 describes infrared therapy devices as an array of infrared diodes on a flexible pad held against the skin, and that device category is non-covered for diabetic and non-diabetic peripheral sensory neuropathy. A laser differs in wavelength, coherence, power and delivery, and a coverage decision is a payment judgment rather than a trial result. See alternative medicine approaches to peripheral neuropathy.

Should I have nerve testing before trying laser therapy?

Testing first tells you which fibers are involved and whether the pattern is length-dependent, focal or small-fiber, and that changes what is worth trying. Nerve conduction studies mainly assess large myelinated fibers, so they can read normal when small fibers are the problem — which is also why a trial using them as an endpoint can miss an effect. See small fiber neuropathy symptoms and testing.

Does laser therapy help if my neuropathy is not diabetic?

Most of the low-level laser evidence was gathered in diabetic polyneuropathy. Two class 4 trials studied chemotherapy-induced neuropathy, one reporting a large reduction in neuropathy scores and one finding no significant difference from sham on its primary endpoint. Autoimmune, nutritional and toxic drivers have not been tested this way, and the plan should still target the driver doing the damage. See diabetic peripheral neuropathy treatment in St. Louis.

Sources

1. Zinman LH, Ngo M, Ng ET, Nwe KT, Gogov S, Bril V. “Low-intensity laser therapy for painful symptoms of diabetic sensorimotor polyneuropathy: a controlled trial.” Diabetes Care. 2004;27(4):921–924. https://doi.org/10.2337/diacare.27.4.921
2. Bashiri H. “Evaluation of low level laser therapy in reducing diabetic polyneuropathy related pain and sensorimotor disorders.” Acta Medica Iranica. 2013;51(8):543–547. https://acta.tums.ac.ir/index.php/acta/article/view/4395
3. Anju M, Ummer Velladath S, Arun Maiya G, Hande M. “A single blinded randomized controlled trial assessing the effect of photobiomodulation therapy on neuron specific biomarkers in type II diabetes mellitus patients with peripheral neuropathy.” Diabetes Research and Clinical Practice. 2025;222:112087. https://doi.org/10.1016/j.diabres.2025.112087
4. U.S. Food and Drug Administration. “21 CFR 1040.10 — Laser products.” Code of Federal Regulations, current edition. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-J/part-1040/section-1040.10
5. Hadis MA, Zainal SA, Holder MJ, Carroll JD, Cooper PR, Milward MR, Palin WM. “The dark art of light measurement: accurate radiometry for low-level light therapy.” Lasers in Medical Science. 2016;31(4):789–809. https://pmc.ncbi.nlm.nih.gov/articles/PMC4851696/
6. Clinical Trials Registry – India. “Effect of Low Level Laser Therapy on Neuropathic Pain Specific Markers in Diabetic Peripheral Neuropathy — A Single Blinded Randomised Control Trial.” CTRI/2018/04/013540, registered April 27, 2018. WHO International Clinical Trials Registry Platform record. https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2018/04/013540
7. Anju M, Saleena Ummer V, Arun G Maiya, Manjunath Hande. “Low level laser therapy for the patients with painful diabetic peripheral neuropathy — A systematic review.” Diabetes & Metabolic Syndrome. 2019;13(4):2667–2670. https://doi.org/10.1016/j.dsx.2019.07.035
8. de Souza V, da Palma Cruz M, Chaves Bittencourt C, et al. “Dosimetric parameters and clinical outcomes of photobiomodulation in diabetic neuropathy: a concise review.” Lasers in Medical Science. 2025;40:436. https://doi.org/10.1007/s10103-025-04701-7
9. Chatterjee P, Srivastava AK, Kumar DA, Chakrawarty A, Khan MA, Ambashtha AK, Kumar V, De Taboada L, Dey AB. “Effect of deep tissue laser therapy treatment on peripheral neuropathic pain in older adults with type 2 diabetes: a pilot randomized clinical trial.” BMC Geriatrics. 2019;19:218. https://pmc.ncbi.nlm.nih.gov/articles/PMC6689877/
10. Argenta PA, Ballman KV, Geller MA, Carson LF, Ghebre R, Mullany SA, Teoh DGK, Winterhoff BJN, Rivard CL, Erickson BK. “The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial.” Gynecologic Oncology. 2017;144(1):159–166. https://doi.org/10.1016/j.ygyno.2016.11.013
11. Lodewijckx J, Robijns J, Claes M, et al. “The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial).” Supportive Care in Cancer. 2022;30(6):5509–5517. https://pmc.ncbi.nlm.nih.gov/articles/PMC8935622/
12. Centers for Medicare & Medicaid Services. “NCD 270.6, Infrared Therapy Devices.” Effective October 24, 2006; implementation January 16, 2007. Medicare Coverage Database. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=315&ncdver=1
13. Centers for Medicare & Medicaid Services. “Proposed Decision Memorandum for Infrared Therapy Devices (CAG-00291N).” July 26, 2006. Medicare Coverage Database. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaId=176
14. Farouk S, Abdullah AA. “Laser therapy for neuropathic pain and neuroinflammatory skin disorders: A comprehensive overview.” CosmoDerma. 2025;5:125. https://cosmoderma.org/laser-therapy-for-neuropathic-pain-and-neuroinflammatory-skin-disorders-a-comprehensive-overview/

Yes, peripheral neuropathy can improve, but how much it improves depends on which driver is damaging the nerve and how long that driver has been active. Cleveland Clinic states that it is possible to stop or improve certain types of neuropathy when they are diagnosed and treated quickly.¹ For damage that has been building for years, realistic goals shift toward less burning, better protective sensation and safer walking.

Peripheral neuropathy is the term for any type of nerve damage outside the brain and spinal cord.¹ That single definition is why the honest answer varies so much from person to person. The label tells you where the injury is. It does not tell you what is causing it.

Key takeaways

• Neuropathy is a category, not a diagnosis. What can improve depends on the driver, not the label.
• Most stalled cases are cases where the driver was never identified. Treatment aimed at the wrong mechanism tends to plateau.
• Testing narrows the question. Electrodiagnostic testing (EMG and nerve conduction studies) is performed on site and helps show which nerve fibers are involved.
• Timing matters. A driver that is caught early is a different problem from one that has been running for a decade.
• For long-standing damage, the goals change. Less burning, more reliable sensation and steadier walking are the targets, not nerve regrowth.

Improvement depends on the driver, not the label

Two people can describe the same burning feet and the same numbness and have entirely different mechanisms underneath. One may have an active metabolic problem. Another may have a nutritional deficiency, an autoimmune process, a toxic exposure or a structural compression.

That is why the useful question is not “how bad is my neuropathy.” It is “what is still injuring my nerves right now, and can that be reduced.”

The five driver categories we work through

• Metabolic drivers, including the nerve injury seen in diabetes
• Nutritional drivers, including B12 deficiency
• Autoimmune and infectious drivers
• Toxic and environmental drivers
• Structural and compressive contributors

Medication that turns down the signal does not repair the wiring. If the driver is still active, symptoms tend to return whenever the dose is lowered.

What counts as improvement

Improvement is not one number. It is a set of changes that matter to daily function and to safety.

Goals that are realistic to discuss

• Less burning at night and fewer hot-coal sensations
• Better protective sensation, so you notice pressure before the skin breaks down
• Less numbness and more reliable feedback from the feet, which supports steadier walking
• Fewer electric, shooting misfires
• Stabilization, when the driver exposure has been reduced

What we do not promise

We do not promise nerve regeneration, reversal or a cure. When nerve injury has had years to accumulate, the honest framing is rehabilitation of the nerve environment and better function, not a return to how your feet felt before symptoms started.

Why the physical exam still carries most of the weight

In diabetic peripheral neuropathy, StatPearls notes that peripheral neuropathy is primarily diagnosed clinically.² Your history, the pattern of symptoms and the examination findings carry a great deal of the diagnostic weight, and testing is used to answer specific questions raised by that exam.

Mapping before choosing a treatment

• On-site electrodiagnostic testing (EMG and nerve conduction studies) to evaluate nerve function
• Driver evaluation across metabolic, nutritional, autoimmune, toxic and structural contributors
• A plan that follows the finding, rather than a fixed sequence applied to everyone

When diabetes is the driver

Diabetic peripheral neuropathy is a metabolic and microvascular problem that happens to show up in the feet. How much can improve depends largely on how much of that metabolic injury is still active, which is why glucose control and vascular support sit inside the treatment plan rather than beside it. Our approach for patients in this situation is outlined on the diabetic peripheral neuropathy treatment page.

Why the timeline matters

High blood sugar drives a chemical reaction inside the body that is chemically related to the browning of sugar under heat. The longer that process runs unchecked, the more of the nerve’s supporting environment is affected. You can read how that process damages nerve tissue in our article on glycation and nerve damage.

Where light-based and energy-based therapies fit

Class 4 photobiomodulation, class 3B cold laser and whole-body infrared are used at Regenerve as part of a broader plan aimed at the nerve environment. They are not a stand-alone answer, and they are not a substitute for identifying the driver.

When light therapy is added without knowing what is injuring the nerve, the result is unpredictable. When it is added to a plan that also reduces the active driver, it has a defined job inside that plan.

When the diagnosis comes back “idiopathic”

Many people arrive with an idiopathic label, which usually means the driver was not identified during the previous workup. That is a fork in the road, because a driver that has not been found cannot be reduced.

Small fiber involvement, nutritional deficiency, gluten-related mechanisms, autoimmune processes and toxic exposures are all worth working through before accepting that no cause exists. Some of these are found on a second look precisely because the first workup was aimed elsewhere.

Regenerve in the St. Louis region

Regenerve treats peripheral neuropathy for patients across the St. Louis region, Missouri and Illinois, including Edwardsville, Glen Carbon, Collinsville, Troy and Maryville. The clinic is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport.

Call or text (314) 886-5902, or email info@regenerve.com. Hours are Monday through Thursday 9:00 to 16:00 and Friday 9:00 to 13:30.

Your next step

If you want a structured starting point, the free five-question Nerve Damage Score identifies which driver category most likely applies to you, and your answers guide what we evaluate first.

Frequently asked questions

Can peripheral neuropathy improve if both of my feet are affected?

It can. A symmetric, feet-first pattern is common when a metabolic or nutritional driver is at work, and identifying that driver is what changes the outlook. The evaluation, including on-site electrodiagnostic testing, is described on our neuropathy services page.

My neuropathy was called idiopathic. Does that mean nothing can be done?

Not necessarily. Idiopathic usually means the driver has not been identified yet, not that no driver exists. See the hidden drivers of peripheral neuropathy.

Why do my symptoms feel worse than my test results suggest?

Small nerve fibers carry burning, pins and needles and temperature sensation, and they can be injured while routine nerve conduction testing still looks close to normal. See small fiber neuropathy symptoms and testing.

What can I realistically expect for burning feet at night?

Burning at night is one of the symptoms most likely to respond when the underlying driver is addressed, though the timeline varies and no one can promise a specific result. See burning feet and nerve pain.

Sources

1. Cleveland Clinic, “Peripheral Neuropathy,” Cleveland Clinic health library, last updated July 16, 2026, https://my.clevelandclinic.org/health/diseases/14737-peripheral-neuropathy
2. Bodman MA, Dreyer MA, Varacallo MA, “Diabetic Peripheral Neuropathy,” StatPearls, Treasure Island (FL): StatPearls Publishing, last updated February 25, 2024, https://www.ncbi.nlm.nih.gov/books/NBK442009/

Burning feet at night are usually a nerve signal rather than a foot problem. Burning feet syndrome is characterized by sensations of heat or burning that often worsen at night, and peripheral neuropathy — damage to the peripheral sensory nerves — is one of its main causes [1]. The useful next step is not a different cream, it is identifying which driver is injuring the nerve.

That distinction matters because the list of drivers is long and they do not respond to the same treatment. Diabetes, alcohol use disorder and hypothyroidism are all among the conditions Cleveland Clinic lists as causes of the peripheral nerve damage behind burning feet [1].

Why night is when it gets loud

Burning that intensifies after you lie down is one of the defining features of the syndrome [1]. During the day, movement, weight-bearing and distraction compete with the signal. At night none of that is happening, and the signal has the field to itself.

This is also why sedating or numbing the sensation alone tends to disappoint. Turning the volume down does not change what is generating the sound.

The differential worth working through

Neuropathy is a category, not a diagnosis. Your job is to describe the pattern accurately; the evaluation’s job is to determine which driver fits it.

Metabolic drivers

Both type 1 and type 2 diabetes can affect the peripheral nerves [1], and diabetic peripheral neuropathy is one of the most common reasons for nocturnal burning. Glucose is rarely the whole story on its own — the metabolic and microvascular picture around it usually matters as much.

For the chemistry that connects glucose stress to nerve injury, see glycation and how sugar damages nerves.

Nutritional drivers

Vitamin B levels are part of the standard laboratory workup for burning feet [1]. When nutrient status is off, the raw materials for nerve maintenance are not arriving, and no amount of symptom control changes that.

Toxic and medication-related drivers

Alcohol use disorder is listed among the conditions that damage peripheral nerves [1]. Chemotherapy agents and heavy metal exposure belong on the same list. Exposure history is diagnostic data, and the absence of an obvious exposure is not the same as the absence of a cause.

Skin and local drivers that mimic nerve pain

Athlete’s foot causes itching, burning and stinging between the toes and on the soles [1], which is easy to read as neuropathy. Checking the skin costs nothing and occasionally ends the investigation on the first visit.

How the evaluation is built

The point of testing is not to accumulate results, it is to narrow the driver. Our approach to the drivers that most often go unidentified is described in the hidden drivers of peripheral neuropathy.

Laboratory work

The workup Cleveland Clinic describes includes blood glucose level testing, a complete blood count, and serum and urine electrolytes including magnesium, sodium, potassium and vitamin B levels [1]. These answer a specific question: does the nerve environment have what it needs, and is anything actively injuring it.

Electrodiagnostic testing

Electromyography helps determine the cause of the pain, and nerve conduction velocity testing measures the speed of electrical impulses along the nerve [1]. We perform electrodiagnostic testing (EMG and nerve conduction studies) on site, so results are read in the context of your history rather than arriving weeks later as a separate report.

When the tests and the symptoms disagree

A normal nerve conduction study does not rule out neuropathy. Nerve conduction testing evaluates large fibers, while burning and temperature sensation travel on small fibers. Skin biopsy is the reference method for small fiber neuropathy, and loss of intraepidermal nerve fibers is described as the primary morphological indicator and the only objective assessment that confirms a suspicion of small fiber neuropathy [2].

What treatment follows the driver

Once the driver is identified, the plan follows it. Metabolic and nutritional care addresses the terrain. Where in-clinic therapy is appropriate, our confirmed options include class 4 photobiomodulation, class 3B cold laser and whole-body infrared, used inside a driver-matched plan rather than as a standalone answer.

Qutenza (capsaicin 8% patch)

Qutenza is FDA-approved in adults only for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. Use for any other neuropathy driver is off-label and we describe it that way. It is applied in the clinic by a clinician, is never dispensed for home use, and is repeated no more often than every three months.

Orthobiologic injections

We offer orthobiologic injections (PRP and BMAC). We do not present it otherwise, and we do not promise nerve regeneration or reversal of established nerve damage.

What to bring to the visit

Bring the timeline. When the burning started, whether it began in the toes, what makes it worse, and your diabetes, alcohol, medication and nutritional history are the details that shape which tests are worth running.

Bring your prior results too, including any nerve study that was called normal. A normal large-fiber study is itself a finding when the symptoms are small-fiber in character.

Frequently asked questions

Why do my feet burn more at night than during the day?

Burning feet syndrome is characterized by sensations of heat or burning that often worsen at night [1]. Lying down removes the distractions and the postural changes of the day, and the nerve signal that was there all along becomes the loudest thing in the room. What the pattern of burning and numbness tells us is covered in peripheral neuropathy of the feet, symptoms and patterns.

My nerve conduction study was normal but my feet still burn. What now?

Nerve conduction studies test large nerve fibers. Burning, heat and temperature sensation are carried by small fibers, which can be injured while a conduction study still looks close to normal. Skin biopsy is the reference method for small fiber neuropathy, because loss of intraepidermal nerve fibers is the objective finding that confirms the suspicion [2]. See small fiber neuropathy symptoms and testing.

Could this be a skin problem rather than a nerve problem?

It can be, and it is worth ruling out early. Athlete’s foot causes itching, burning and stinging between the toes and on the soles [1], and inflamed skin adds sensory input that can be mistaken for nerve pain. Treating sensation without checking the skin is how that gets missed — see peripheral neuropathy treatments for the feet.

Which lab tests are worth running?

The workup Cleveland Clinic describes includes blood glucose, a complete blood count, and serum and urine electrolytes including vitamin B levels; hypothyroidism is also among the listed causes [1]. Nutritional results in particular deserve a careful read rather than a normal-or-not glance — see functional B12 deficiency and neuropathy.

Start with the Nerve Damage Score

The Nerve Damage Score is a free five-question assessment that helps identify which driver is most likely behind your symptoms, so your evaluation starts with a direction instead of a guess.

Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134. Serving the St. Louis region, Missouri and Illinois, minutes from St. Louis Lambert International Airport.

Sources

1. Cleveland Clinic. “Burning Feet (Grierson-Gopalan) Syndrome.” Last reviewed 17 July 2023. https://my.clevelandclinic.org/health/symptoms/17773-burning-feet-syndrome — cited for sensations of heat or burning that often worsen at night; peripheral neuropathy as one of the main causes and its definition as damage to the peripheral sensory nerves; type 1 and type 2 diabetes, alcohol use disorder and hypothyroidism among the causes; athlete’s foot causing itching, burning and stinging between the toes and on the soles; and the workup including blood glucose testing, complete blood count, serum and urine electrolytes (magnesium, sodium, potassium, vitamin B levels), electromyography and nerve conduction velocity testing.
2. Samolis A, Troupis T, Politis C, et al. “Intraepidermal Nerve Fiber Density as an Indicator of Neuropathy Predisposition: A Systematic Review with Meta-Analysis.” Diagnostics, 2025;15(11):1311. DOI: 10.3390/diagnostics15111311. https://pmc.ncbi.nlm.nih.gov/articles/PMC12154223/ — cited for skin biopsy as the reference method for diagnosing small fiber neuropathy and for loss of intraepidermal nerve fibers being the primary morphological indicator and the only objective assessment that confirms a suspicion of small fiber neuropathy.

Autonomic neuropathy is damage to the nerves that control automatic body functions, and the reason it goes unrecognized for years is that its symptoms arrive dressed as organ problems. Lightheadedness on standing, feeling full after a few bites, sweating that has changed, bladder trouble, and pupils that are slow to adjust between light and dark are all documented autonomic symptoms [1]. Each one usually gets referred to a different specialist before anyone asks whether one set of nerves connects them.

The nerves involved regulate heart rate and blood pressure, digestion, bladder and sexual function, sweating and temperature control, and pupil response [1]. When those signals fail, the body looks like it is having several unrelated problems at once.

Why the pattern gets filed under other organs

Autonomic symptoms are scattered by design. The autonomic nervous system reaches nearly every organ, so damage to it produces complaints in nearly every clinic, and each complaint is plausible on its own terms.

That is the mechanism behind the long delay to diagnosis. The symptoms are not vague, they are distributed — and distributed symptoms get split up rather than added together.

Lightheadedness or fainting when you stand

Nerve damage may cause you to feel light-headed or faint when you stand up or during physical activity, and it can also cause a rapid heart rate or sudden changes in heart rate [1]. In some people it prevents the chest pain that would normally signal a heart problem [1].

Why it is usually blamed on dehydration

Orthostatic symptoms look like low blood volume or a blood pressure medication effect, and sometimes they are. When the pattern keeps returning after fluids and medication adjustments, that is the point to ask whether the reflex itself is intact.

Digestion that changes without a structural cause

Autonomic damage can cause bloating, fullness and nausea, constipation, vomiting, and diarrhea that is often worse at night [1]. It may also cause gastroparesis, which slows or stops the movement of food from the stomach into the small intestine [1].

Why the workup usually starts elsewhere

Reflux care, irritable bowel pathways and gallbladder imaging are reasonable first moves, and they are what most people get. They are also why the nerve driver often waits years for its turn, particularly in someone whose feet were the only thing anyone connected to neuropathy.

Losing the low-blood-sugar warning

Hypoglycemia unawareness means you do not feel the symptoms of low blood glucose, which can allow an episode to become severe before it is recognized [1]. This is a safety problem, not just a comfort problem.

The shakiness and sweating that normally announce a low are themselves autonomic signals. When that circuitry is damaged, the alarm is quiet even though the emergency is real.

Sweating and temperature control

Autonomic damage may cause excessive sweating at night or while eating, or sweat glands may not work at all, which prevents the body from controlling its temperature properly [1].

Patients commonly describe this as hot flashes, a medication side effect or skin sensitivity. The timing of the sweating, and whether it appears alongside the other symptoms on this page, is what separates the explanations.

Pupils that adjust slowly, and trouble driving at night

Nerve damage may make the pupils slow to respond to changes in light and darkness, which causes difficulty adjusting in dark rooms and difficulty with oncoming headlights while driving at night [1].

This is nearly always taken to an eye clinic first, and the vision complaint is genuine. The driver behind it, in this case, is neurologic.

Bladder and sexual function

Nerve damage may make it hard to know when the bladder needs emptying and when it is empty, which can lead to holding urine too long and to infections, or to incontinence [1]. In men it can prevent erection and cause ejaculation problems; in women it can reduce lubrication, sensation and the ability to reach orgasm [1].

When screening is recommended

The American Diabetes Association position statement on diabetic neuropathy advises that all patients be assessed for distal symmetric polyneuropathy starting at diagnosis of type 2 diabetes and five years after the diagnosis of type 1 diabetes, and at least annually thereafter [2]. It further advises that symptoms and signs of autonomic neuropathy be assessed in patients who have microvascular and neuropathic complications [2].

If you already have neuropathy in your feet and any of the symptoms above, that guidance places you squarely in the group that should be asked about autonomic function rather than waiting for it to be volunteered.

What we do with the pattern

Neuropathy is a category, not a diagnosis. We work to identify the specific driver — metabolic, nutritional, autoimmune, toxic or structural — because the driver decides what the plan should be. Our approach to the drivers that most often get missed is described in the hidden drivers of peripheral neuropathy.

What testing adds, and what it does not

We perform electrodiagnostic testing (EMG and nerve conduction studies) on site. Those studies evaluate peripheral nerve function; they do not measure autonomic function, so they narrow the question rather than answer it.

Where dizziness needs sorting out, we use VNG (videonystagmography), a diagnostic test of inner-ear balance function. VNG is a test only — it tells us whether the inner ear is contributing to your dizziness, and it does not treat anything.

What comes before treatment

The first work is history and pattern mapping: when the symptoms occur, what triggers them, and what your diabetes, alcohol, medication and nutritional history looks like. Bring that timeline to the visit. It is the most useful thing you can bring, and it is the part no test can supply.

Frequently asked questions

How is autonomic neuropathy different from the neuropathy in my feet?

The neuropathy most people know about affects sensation in the feet and hands — burning, numbness, pins and needles. Autonomic neuropathy affects the nerves that run the body automatically: blood pressure on standing, stomach emptying, bladder emptying, sweating and pupil response [1]. The two often travel together in the same person. See peripheral neuropathy of the feet, symptoms and patterns.

Why do these symptoms get blamed on something else for so long?

Because each one lands in a different specialty. Lightheadedness on standing looks cardiac, early fullness and nausea look gastrointestinal, and slow pupil adjustment looks ophthalmic, so the shared nerve driver is rarely the first thing anyone tests for. Small nerve fibers carry much of this traffic — see small fiber neuropathy symptoms and testing.

When should someone with diabetes be screened?

The American Diabetes Association position statement advises assessing all patients for distal symmetric polyneuropathy starting at diagnosis of type 2 diabetes and five years after diagnosis of type 1 diabetes, and at least annually thereafter, and assessing symptoms and signs of autonomic neuropathy in patients who have microvascular and neuropathic complications [2]. Our evaluation when diabetes is the driver is described on our diabetic peripheral neuropathy treatment page.

What if I do not have diabetes and no one can find a cause?

Autonomic symptoms still need a driver, and idiopathic usually means the driver has not been identified yet. Nutritional deficiency is one of the categories worth ruling in or out before the label sticks — see functional B12 deficiency and neuropathy.

What testing does Regenerve perform on site?

We perform electrodiagnostic testing (EMG and nerve conduction studies) on site, and we use VNG (videonystagmography) as a diagnostic test of inner-ear balance function when dizziness needs to be sorted out. VNG is a test, not a treatment. The full list is on our neuropathy services page.

Start with the Nerve Damage Score

The Nerve Damage Score is a free five-question assessment that helps identify which driver is most likely behind your symptoms, so your evaluation starts with a direction instead of a guess.

Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134. Serving the St. Louis region, Missouri and Illinois, minutes from St. Louis Lambert International Airport.

Sources

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health. “Autonomic Neuropathy.” Last reviewed February 2018. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies/autonomic-neuropathy — cited for the cardiovascular symptoms (lightheadedness or faintness on standing, rapid or sudden changes in heart rate, absent chest pain), the digestive symptoms and gastroparesis, hypoglycemia unawareness, sweating and temperature-control changes, bladder and sexual dysfunction, and the slow pupil response and night-driving difficulty.
2. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. “Diabetic Neuropathy: A Position Statement by the American Diabetes Association.” Diabetes Care, 2017;40(1):136–154. DOI: 10.2337/dc16-2042. https://pmc.ncbi.nlm.nih.gov/articles/PMC6977405/ — cited for the recommendation to assess all patients for distal symmetric polyneuropathy starting at diagnosis of type 2 diabetes and five years after diagnosis of type 1 diabetes and at least annually thereafter, and to assess symptoms and signs of autonomic neuropathy in patients with microvascular and neuropathic complications.

In diabetic peripheral neuropathy, alpha-lipoic acid probably has little or no effect on neuropathy symptoms compared with placebo. That is the conclusion of a 2024 Cochrane review of three placebo-controlled randomized trials in 816 adults with type 1 or type 2 diabetes, which found a mean difference of −0.16 points on symptom scores at six months and low-certainty evidence of little or no effect on impairment [1]. An American Family Physician summary of the same review reported the same picture at both six and 24 months [2].

That does not make alpha-lipoic acid harmful, and it does not answer every neuropathy question. It means that if your goal is a noticeable change in burning or numbness from diabetic peripheral neuropathy, the trial record does not support expecting it from this supplement on its own.

What “little or no effect” means in plain language

Trial wording can feel evasive, so here is the translation. Across the studied population — adults with diabetes and diabetic peripheral neuropathy, mean age 57.8 years, treated for at least six months at doses between 600 and 1,800 mg per day — the average result on alpha-lipoic acid was close to the average result on placebo [1].

The reviewers also reported little or no difference in adverse events that caused people to stop treatment [1][2]. So the honest summary is not that this supplement is dangerous. It is that it is unlikely to change how your feet feel.

What the review actually measured

The primary outcome was change in neuropathy symptoms six months after randomization, measured with validated instruments such as the Total Symptom Score. Secondary outcomes included symptoms at 24 months, impairment at six and 24 months, and adverse events leading to discontinuation [1].

Certainty was downgraded because of loss to follow-up and imprecision, particularly for impairment [1]. That distinction is worth keeping: the finding is not that the supplement was proven useless, it is that no signal appeared on evidence of moderate and low certainty.

Why one supplement rarely moves a neuropathy

Peripheral neuropathy is a category, not a diagnosis. Nerve injury can be driven by metabolic stress, nutritional deficiency, autoimmune activity, toxic exposure or structural compression, and those drivers do not answer to the same intervention.

That is why the first question in our clinic is not which supplement to add, it is which driver is doing the most damage right now. You can read how we approach the drivers that commonly get missed in the hidden drivers of peripheral neuropathy.

When the driver is metabolic

When the dominant driver is metabolic, the plan has two parallel goals: reduce the ongoing metabolic pressure on nerve fibers and their microcirculation, and support the nerve environment while that pressure comes down. A supplement added on top of an unchanged metabolic picture is working against the current.

For the chemistry behind that, see our explainer on glycation and how sugar damages nerves.

When the driver is not metabolic

Nutritional deficits, gluten-associated patterns, toxic and environmental exposures, autoimmune activity and chemotherapy-related nerve injury all produce peripheral nerve symptoms, and none of them were the population studied in the alpha-lipoic acid trials.

A label of idiopathic usually means the driver has not been mapped yet, not that no driver exists. That is a reason to keep looking, not a reason to rotate supplements.

What we do instead of guessing

We perform electrodiagnostic testing (EMG and nerve conduction studies) on site, so nerve conduction findings are interpreted alongside your history rather than arriving as a separate report weeks later. We pair that with metabolic and nutritional evaluation to check whether the terrain has what nerves need.

Where in-clinic therapy is appropriate, our confirmed options include class 4 photobiomodulation, class 3B cold laser and whole-body infrared. These are used inside a driver-matched plan rather than as a standalone answer, and we do not promise nerve regeneration or reversal of established nerve damage.

Where alpha-lipoic acid can still sit in a plan

Some patients arrive already taking it and tolerate it well. Our position is that it can remain one element of metabolic and nutritional support as long as it is not displacing the work that actually changes the driver, and that the trial evidence should set your expectations for what it will do.

Frequently asked questions

Does alpha-lipoic acid help diabetic peripheral neuropathy?

Probably not to a degree you would notice. A 2024 Cochrane review of three placebo-controlled trials in 816 adults with diabetes concluded that alpha-lipoic acid probably has little or no effect on neuropathy symptoms at six months, and may have little or no effect on impairment [1]. Our approach when diabetes is the driver is described on our diabetic peripheral neuropathy treatment page.

Does taking it for longer work better?

Not according to the published record. An American Family Physician summary of the same Cochrane review reported little or no effect compared with placebo on symptoms and impairment at both six and 24 months [2]. When a nutritional driver is the real problem, correcting that deficiency is a different question — see functional B12 deficiency and neuropathy.

Do these results apply to me if my neuropathy is not from diabetes?

No. The trials enrolled adults with type 1 or type 2 diabetes and diabetic peripheral neuropathy [1], so the finding cannot be transferred to autoimmune, toxic, nutritional or idiopathic drivers. Burning pain that persists when routine nerve conduction testing looks close to normal points somewhere else — see small fiber neuropathy symptoms and testing.

If not a supplement, what is the first useful step?

Identifying which driver is active, then matching testing to that pattern. We perform electrodiagnostic testing (EMG and nerve conduction studies) on site and read it alongside metabolic and nutritional evaluation rather than adding one variable at a time. See our neuropathy services.

Start with the Nerve Damage Score

The Nerve Damage Score is a free five-question assessment that helps identify which driver is most likely behind your symptoms, so your evaluation starts with a direction instead of a guess.

Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134. Serving the St. Louis region, Missouri and Illinois, minutes from St. Louis Lambert International Airport.

Sources

1. Baicus C, Purcarea A, von Elm E, Delcea C, Furtunescu FL. “Alpha-lipoic acid for diabetic peripheral neuropathy.” Cochrane Database of Systematic Reviews, 2024, Issue 1, Art. No.: CD012967. Published 11 January 2024. DOI: 10.1002/14651858.CD012967.pub2. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012967.pub2/full — cited for the three included placebo-controlled trials, 816 adult participants with type 1 or type 2 diabetes, mean age 57.8 years, doses of 600–1,800 mg per day, the −0.16-point symptom difference and −1.02-point impairment difference at six months, the outcome definitions, and the certainty downgrades for loss to follow-up and imprecision.
2. Abuali SM, Frasca DJ. “Alpha-Lipoic Acid for Diabetic Peripheral Neuropathy.” American Family Physician, February 2025;111(2):119–120. https://www.aafp.org/afp/2025/0200/mbtn-alpha-lipoic-acid-diabetic-peripheral-neuropathy — cited for little or no effect versus placebo on symptom reduction and impairment at six and 24 months, and little or no difference in adverse events.

Supporting someone with peripheral neuropathy comes down to three jobs you can actually influence: keeping them safe from falls and unnoticed foot injuries, keeping a record that helps the care team find the driver behind the nerve damage, and keeping the plan going between visits. You do not need a medical background to do any of them well. What you need is a method, so the visit stops being a guessing session.

This guide covers what to watch at home, what to ask for at appointments, and when not to wait.

What you are really supporting

Peripheral neuropathy looks like a foot problem, but the nerve is usually reacting to something upstream. Neuropathy is a category, not a diagnosis, and the useful question is always which driver is doing the damage: metabolic, nutritional, autoimmune, toxic, or structural.

That distinction changes your role. If the driver is still active, symptom relief alone will keep slipping, and the things you track at home become the evidence that helps a clinician narrow it down.

Learn the driver categories well enough to ask about them

• Metabolic and microvascular problems, including the perfusion changes seen in diabetic peripheral neuropathy.
• Nutritional deficits, which can be present even when routine labs are read as normal.
• Autoimmune drivers, including neuropathy alongside lupus or rheumatoid arthritis.
• Toxic exposures, including medications, alcohol, chemotherapy and heavy metals.
• Structural causes such as nerve compression, which can coexist with a systemic neuropathy.

A full breakdown of these is in the hidden drivers of peripheral neuropathy. Reading it before an appointment is usually worth more than any list of questions you could copy down.

Job one: prevent the injuries that neuropathy hides

When protective sensation is reduced, the floor feels different, balance changes, and an injury can happen without any pain to announce it. Most of what a caregiver contributes here is environmental and repeatable.

A home safety pass you can run weekly

• Check footwear and fit. Closed-toe shoes with supportive soles, worn indoors as well as outdoors.
• Remove loose rugs, cords and clutter along the routes used most.
• Improve lighting in hallways and on the path to the bathroom.
• Move everyday items to reachable heights, so there is less bending and twisting.
• Take over water-temperature checks. A foot that cannot feel heat will not report a burn.
• Look at the soles and between the toes. A mirror makes this easier than it sounds.

Nights are their own problem

When symptoms flare after dark, a caregiver often becomes the de facto sleep manager. Keeping the bedroom cool and the bedding smooth helps some people, and both are easy to try.

The more useful contribution is the record. Note when the burning started, what the day looked like beforehand, and whether a medication or meal timing had shifted. Patterns show up in a log that nobody can reconstruct from memory in a fifteen-minute visit.

Job two: bring information, not impressions

Clinicians can only work with what they are told. A caregiver who arrives with dates, a medication list, prior lab results and a two-week symptom log changes what is possible in that appointment.

What is worth writing down

• When symptoms are worst, and what makes them better or worse.
• Recent medication changes, including doses that were started or stopped.
• Any new weakness, change in gait, or difficulty with stairs.
• Foot findings: redness that does not fade, new callus, blisters, cracks, drainage.
• For a history of chemotherapy or occupational exposure, the dates and agents involved.

When to push for clearer diagnostic mapping

Ask for more clarity if the pattern is unclear, if symptoms are progressing quickly, or if the current plan does not match what the person actually needs to be able to do. Electrodiagnostic testing, performed on site at Regenerve, can help define which nerve fibers are involved and whether the pattern is mainly sensory or motor.

What to expect from the treatments that get discussed

Several of the therapies used for neuropathy get described loosely in general conversation, and a caregiver is often the person who ends up explaining them again at home. A few are worth getting exactly right.

Balance testing is a test, not a treatment

Videonystagmography, or VNG, measures inner-ear balance function. It is diagnostic. It can show whether an inner-ear problem is contributing to unsteadiness beyond what neuropathy explains, which matters for fall risk, but it does not treat anything.

Qutenza has a narrow approved indication

Qutenza, the capsaicin 8% patch, is FDA-approved in adults only for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. Use for any other driver of neuropathy is off-label, and the clinician should describe it that way.

It is applied in the office by a clinician, never dispensed for home use, and repeated no more often than every three months. Plan around the application day and note afterward how night-time symptoms respond.

Orthobiologic injections at Regenerve

Where orthobiologic injections such as PRP and BMAC are discussed, it is fair to ask what outcome the clinician expects to see and over what period.

Job three: keep yourself functional

Caregiver strain is not a soft issue here. When you are exhausted, appointments slip, medication schedules drift and the symptom log stops getting updated, and the plan degrades along with it. The 2025 national caregiving report from AARP and the National Alliance for Caregiving documents emotional stress and physical strain as widespread among US family caregivers [1][2].

• Pick one daily check-in moment for symptoms rather than monitoring all day.
• Keep one shared calendar for appointments, refills and therapy days.
• Hand off what can be handed off, including transportation and meal prep.
• Protect your own sleep. Judgment and safety awareness both degrade with fatigue.

When not to wait

Most neuropathy is chronic and slow. These are the exceptions, and they warrant a call to the treating clinician or emergency services rather than a wait-and-see:

• New weakness, a rapidly worsening gait, or a sudden change in the ability to walk.
• A fall, a head injury, or an inability to get up safely afterward.
• Any open wound, drainage, new odor, or a hot, swollen foot.
• A sharp escalation in pain that does not match the prior pattern, particularly soon after a new medication.

Frequently asked questions

What should a caregiver do first when someone’s feet are numb?

Start with safety. Clear trip hazards, check that footwear fits and is worn indoors and out, and take over water-temperature checks, because a foot that cannot feel heat cannot warn anyone. Then push for a workup that identifies the driver rather than only treating the sensation. See the hidden drivers of peripheral neuropathy.

How can I help at home when burning feet keep my loved one awake?

Record when the burning starts, what preceded it, and how it affects sleep, then bring that log to the next visit. Home observation is often the only way a clinician learns whether a change in the plan actually helped. See peripheral neuropathy of the feet symptoms.

Is balance testing a treatment for neuropathy?

No. Videonystagmography, or VNG, is a diagnostic test of inner-ear balance function. It can show whether an inner-ear problem is adding to unsteadiness that neuropathy alone does not explain, but it does not treat anything. See VNG balance testing for neuropathy patients.

My loved one was offered the capsaicin 8% patch. What should I know?

Qutenza is FDA-approved in adults only for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. Any other use is off-label and the clinician should say so. It is applied in the office by a clinician, never sent home, and repeated no more often than every three months. See the Qutenza capsaicin 8% patch page.

Start with a map, not a guess

The most useful thing a caregiver can bring to the next appointment is a clearer sense of which driver is most likely responsible. The free five-question Nerve Damage Score at regenerve.com/assessment is built for exactly that conversation, and it takes a few minutes to complete together.

Sources

1. AARP and National Alliance for Caregiving, Caregiving in the US 2025, 2025, https://www.caregiving.org/research/caregiving-in-the-us/.
2. AARP Public Policy Institute, Caregiving in the US 2025 (report landing page), 2025, https://www.aarp.org/pri/topics/ltss/family-caregiving/caregiving-in-the-us-2025/.